[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200200510A1 - 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр - Google Patents

4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр

Info

Publication number
EA200200510A1
EA200200510A1 EA200200510A EA200200510A EA200200510A1 EA 200200510 A1 EA200200510 A1 EA 200200510A1 EA 200200510 A EA200200510 A EA 200200510A EA 200200510 A EA200200510 A EA 200200510A EA 200200510 A1 EA200200510 A1 EA 200200510A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
tetrahydrochinoline
cetr
carboxyamino
ethyl
Prior art date
Application number
EA200200510A
Other languages
English (en)
Inventor
Дуглас Джон Мелдрум Эллен
Трой Энтони Эпплтон
Лайл Робинсон Бростром
Дерек Лоренс Тикнер
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200200510A1 publication Critical patent/EA200200510A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Описываются кристаллические формы ингибитора СЕТР формулы (I), способы получения кристаллических форм, способы применения кристаллических форм и фармацевтические композиции, содержащие кристаллические формы.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200510A 1999-11-30 2000-11-14 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр EA200200510A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30
PCT/IB2000/001650 WO2001040190A1 (en) 1999-11-30 2000-11-14 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor

Publications (1)

Publication Number Publication Date
EA200200510A1 true EA200200510A1 (ru) 2002-10-31

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200510A EA200200510A1 (ru) 1999-11-30 2000-11-14 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр

Country Status (28)

Country Link
EP (1) EP1246804A1 (ru)
JP (1) JP2003515592A (ru)
KR (1) KR20020058057A (ru)
CN (1) CN1402711A (ru)
AP (1) AP2002002531A0 (ru)
AU (1) AU1048801A (ru)
BG (1) BG106854A (ru)
BR (1) BR0015836A (ru)
CA (1) CA2392979A1 (ru)
CO (1) CO5271716A1 (ru)
EA (1) EA200200510A1 (ru)
EC (1) ECSP003792A (ru)
EE (1) EE200200277A (ru)
GT (1) GT200000199A (ru)
HU (1) HUP0203521A2 (ru)
IL (1) IL149097A0 (ru)
IS (1) IS6338A (ru)
MA (1) MA26845A1 (ru)
MX (1) MXPA02005354A (ru)
NO (1) NO20022558D0 (ru)
OA (1) OA12099A (ru)
PA (1) PA8506301A1 (ru)
PE (1) PE20010904A1 (ru)
PL (1) PL355892A1 (ru)
TN (1) TNSN00231A1 (ru)
TR (1) TR200201446T2 (ru)
UY (1) UY26454A1 (ru)
WO (1) WO2001040190A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EA200301139A1 (ru) 2001-06-21 2004-12-30 Пфайзер Продактс Инк. Самоэмульгирующиеся препараты ингибиторов белка-переносчика эфиров холестерина
GT200200170A (es) * 2001-09-28 2003-05-23 Preparacion de inhibidor de cetp anhidro
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
JP4865989B2 (ja) * 2002-02-01 2012-02-01 ベンド・リサーチ・インコーポレーテッド 改良された噴霧乾燥装置を使用する均質な噴霧乾燥された固体の非晶質薬物分散物を製造する方法
NZ532494A (en) 2002-08-30 2006-03-31 Japan Tobacco Inc Dibenzylamine compound and medicinal use thereof
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
MXPA05005813A (es) 2002-12-20 2005-12-12 Pfizer Prod Inc Formas de dosificacion que comprenden un inhibidor de la cetp y un inhibidor de la hmg-coa reductasa.
CN1795177A (zh) * 2003-03-28 2006-06-28 辉瑞产品公司 作为治疗动脉粥样硬化和肥胖症的cetp抑制剂的 1 , 2 , 4 , －取代的1，2，3，4，－四氢－和1，2二氢－喹啉以及1， 2 , 3 ， 4－四氢－喹喔啉衍生物
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
US7749992B2 (en) 2003-10-08 2010-07-06 Eli Lilly And Company Compounds and methods for treating dislipidemia
CN1942428A (zh) * 2004-04-13 2007-04-04 默克公司 Cetp抑制剂
WO2006012093A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006033004A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds as cetp inhibitors
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
EP1861372A1 (en) 2005-02-24 2007-12-05 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP2134169A2 (en) 2007-03-09 2009-12-23 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
EP3795695A1 (en) 2014-07-30 2021-03-24 F. Hoffmann-La Roche AG Genetic markers for predicting responsiveness to therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
WO1998033775A1 (en) * 1997-02-03 1998-08-06 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
UY26454A1 (es) 2001-07-31
TR200201446T2 (tr) 2002-11-21
PA8506301A1 (es) 2002-08-26
IS6338A (is) 2002-04-12
NO20022558L (no) 2002-05-29
MXPA02005354A (es) 2002-12-11
EE200200277A (et) 2003-10-15
IL149097A0 (en) 2002-11-10
JP2003515592A (ja) 2003-05-07
OA12099A (en) 2006-05-04
GT200000199A (es) 2002-05-23
PL355892A1 (en) 2004-05-31
PE20010904A1 (es) 2001-09-10
CA2392979A1 (en) 2001-06-07
CN1402711A (zh) 2003-03-12
AP2002002531A0 (en) 2002-06-30
HUP0203521A2 (hu) 2003-02-28
MA26845A1 (fr) 2004-12-20
AU1048801A (en) 2001-06-12
BR0015836A (pt) 2002-08-06
TNSN00231A1 (fr) 2002-05-30
BG106854A (bg) 2002-12-29
EP1246804A1 (en) 2002-10-09
KR20020058057A (ko) 2002-07-12
CO5271716A1 (es) 2003-04-30
NO20022558D0 (no) 2002-05-29
ECSP003792A (es) 2002-04-23
WO2001040190A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
DE69413542D1 (de) Perhydroisoindolderivate als substanz p antagonisten
EA200500017A1 (ru) Новые соединения
KR100263496B1 (ko) 탁솔 유도체 및 이의 제조방법
BG103485A (en) Ketobanzamides as calpain inhibitors
NO955047L (no) Sekundære aminer som antidiabetiske og antifedme-midler
NO20025590D0 (no) Fenylglycin-derivater
EA200000826A1 (ru) Галоидированные производные амидиноаминокислот, применимые в качестве ингибиторов no-синтазы
FI934298A0 (fi) Kristallin tiagabine-hydrokloridmonohydrat, dess framstaellning och dess anvaendning
DE50209545D1 (de) Flüssigkristallines medium
EA200400708A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
FI955498A (fi) Nipekotiinihappojohdannaisia hyytymistä estävinä aineina
SE9903290D0 (sv) Novel compounds
EA200000628A1 (ru) Ингибиторы металлопротеаз матрикса
MXPA04009421A (es) Compuestos de tiazol-2-ilimina como inhibidores de la pde-7.
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
TW252979B (ru)
FI963168A0 (fi) Enkefalinaasin inhibiittoreina käyttökelpoisia uusia indaani-2-merkaptoasetyyliamiddisulfidijohdannaisia
ES2128031T3 (es) Forma cristalina y polimorfica de (s,s,s)-n-(1-(2-carboxi-3-(n2-mesilisilamino)propil)-1-ciclopentilcarbonil)tirosina.
DE59803066D1 (de) Substituierte benzyloxyimino-verbindungen
TR200001122T2 (tr) Farmasötikler olarak bifenil türevleri.
FI960588A0 (fi) Mikrobisideina käytettäviä tiokarbamoyyliyhdisteitä
NO20053117L (no) Cyklopenta[c]isoksazol-3-aminer anvendt som materialbeskyttelsesmidler..
SU1690339A1 (ru) N-(3-хлоро-1,4-нафтохинонил-2)-2-d,l-аспарагиновая кислота, проявляющая кардиостимулирующие свойства